olezarsen

Treatment of Familial Chylomicronemia Syndrome

Olezarsen is used to treat adults with familial chylomicronemia syndrome (FCS). This is a rare, inherited disorder that prevents the body from properly breaking down certain types of fats. As a result, people with FCS have extremely high levels of triglycerides in their blood.

Role in Therapy

The medication is used as an add-on to a low-fat diet. Its primary purpose is to lower triglyceride levels, which can help prevent serious health problems like acute pancreatitis (severe inflammation of the pancreas) that are often caused by very high fat levels in the blood.

Usage Guidelines

• This treatment is specifically for adults with a confirmed diagnosis of FCS.
• It has not been approved for use in children or adolescents.
• It must be used in combination with dietary fat restriction to be effective.

Mechanism of Action

Olezarsen is a type of medication known as an antisense oligonucleotide. It works by targeting and blocking the genetic instructions (mRNA) that the body uses to produce a protein called apolipoprotein C-III (apoC-III).

Role of apoC-III

The apoC-III protein is primarily made in the liver and plays a key role in regulating fat levels in the blood. Under normal conditions, this protein inhibits the enzymes responsible for breaking down triglycerides and prevents the liver from clearing certain fat particles from the bloodstream.

How Olezarsen Lowers Triglycerides

By reducing the amount of apoC-III protein available, olezarsen helps the body manage fats more effectively. This results in:

• Increased fat breakdown: Lower levels of apoC-III allow enzymes to more efficiently break down triglycerides.
• Improved clearance: The body can more easily remove triglyceride-rich particles from the blood.

This mechanism helps significantly lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS), a condition where the body cannot properly break down fats.

Common Side Effects

The most frequently reported side effects in clinical studies of olezarsen include:

• Injection site reactions: Redness, pain, itching, or swelling where the medication was injected.
• Abdominal pain: General discomfort or pain in the stomach area.
• Infections: An increased occurrence of sinusitis (sinus infection) or COVID-19.

Serious Side Effects

Olezarsen can cause serious health complications that require regular monitoring by a healthcare provider. These include:

• Low platelet counts (thrombocytopenia): A significant decrease in platelets can increase the risk of severe or life-threatening bleeding. Patients should watch for unusual bruising, nosebleeds, bleeding gums, or small red or purple spots on the skin.
• Kidney toxicity: This medication may cause kidney damage or an increase in protein in the urine. Healthcare providers typically monitor kidney function through regular urine and blood tests.
• Liver toxicity: Olezarsen may cause elevations in liver enzymes, which can indicate liver irritation or injury.
• Hypersensitivity reactions: Serious allergic reactions are possible, though they are less common.

Because of these risks, healthcare providers will perform baseline and periodic blood and urine tests to monitor platelet counts, kidney function, and liver health throughout the course of treatment.

Thrombocytopenia

Olezarsen may cause a significant decrease in the number of platelets in the blood, a condition known as thrombocytopenia. Low platelet levels increase the risk of serious or life-threatening bleeding. Platelet counts are typically measured before starting the medication and monitored regularly throughout treatment.

Kidney Toxicity

There is a risk of kidney damage (renal toxicity) associated with this medication. Healthcare providers generally monitor kidney function by testing for protein in the urine and measuring serum creatinine levels before and during therapy.

Liver Toxicity

Olezarsen may cause elevations in liver enzymes, which can indicate liver injury. Liver function tests are usually performed before the first dose and at regular intervals while taking the drug.

Hypersensitivity Reactions

Serious allergic reactions, including anaphylaxis and angioedema, may occur. If a severe hypersensitivity reaction is suspected, the medication should be discontinued immediately and appropriate medical care sought.

Contraindications

Olezarsen is contraindicated in patients with a known history of hypersensitivity to olezarsen or any of the inactive ingredients in the formulation.

Pregnancy

There are no adequate or well-controlled studies on the use of olezarsen in pregnant women. While animal studies did not show evidence of harm to the fetus at doses significantly higher than the recommended human dose, it is not known if the drug will cause harm to a human pregnancy.

If you are pregnant or planning to become pregnant, talk to your healthcare provider about the potential risks and benefits of continuing or starting this medication.

Breastfeeding

It is currently unknown if olezarsen passes into human breast milk, how it affects milk production, or if it has any effects on a breastfed infant. Because many drugs are excreted in human milk, caution is advised.

Healthcare providers typically consider the developmental and health benefits of breastfeeding alongside the mother's clinical need for the medication and any potential adverse effects on the infant from the drug or the underlying maternal condition.

Dosage Forms

Olezarsen is supplied as a sterile solution for injection. It is administered subcutaneously, which means it is injected into the fatty tissue just under the skin.

This medication is available in the following form:

• Subcutaneous Injection: Provided in a single-dose prefilled syringe.

FDA Approval and Indication

The U.S. Food and Drug Administration (FDA) approved olezarsen in December 2024. It is indicated for use in adults with familial chylomicronemia syndrome (FCS) to help lower triglyceride levels. FCS is a rare genetic condition that prevents the body from breaking down certain fats, often leading to very high triglyceride levels and a risk of acute pancreatitis.

Regulatory Designations

Olezarsen received several special designations from the FDA during its development process to address the unmet medical needs of patients with FCS:

• Orphan Drug Designation: This status is given to drugs intended for the treatment of rare diseases.
• Fast Track Designation: This process is designed to facilitate the development and speed up the review of drugs that treat serious conditions.
• Breakthrough Therapy Designation: This is granted to drugs that may demonstrate substantial improvement over existing therapies for serious conditions.

Safety and Monitoring

There are no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) programs currently required for this medication. Regulatory approval was based on clinical data showing a significant reduction in triglyceride levels compared to a placebo. Healthcare providers typically monitor for potential side effects, such as injection site reactions or changes in laboratory tests, as part of standard clinical practice.

Insurance and Out-of-Pocket Costs

The price of olezarsen is determined by your health insurance plan's formulary and tier placement. As a specialty medication, it may require prior authorization from your insurance company before coverage is approved. Patients may be responsible for a copayment or coinsurance, which is a percentage of the drug's total cost.

Specialty Pharmacy Access

Olezarsen is typically distributed through specialty pharmacies rather than standard retail pharmacies. These pharmacies specialize in handling medications that require specific storage conditions or close monitoring. The cost may vary between different specialty pharmacy providers.

Financial Support Options

Manufacturers of specialty drugs often provide resources to help patients afford treatment. These may include:

• Copay Savings Programs: These can lower out-of-pocket costs for eligible patients with private or commercial insurance.
• Patient Assistance Programs: These programs may provide the medication at no cost or a reduced cost for patients who meet certain financial criteria and lack adequate insurance coverage.

To find the most accurate cost, check with your insurance provider or contact the manufacturer's support services.